Statin use and the risk of colorectal cancer in a population-based electronic health records study
Ibáñez-Sanz, Gemma (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Guinó, Elisabet (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Pontes García, Caridad (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Quijada-Manuitt, María Ángeles (Institut d'Investigació Biomèdica Sant Pau)
de la Peña, Luisa (Hospital de Viladecans)
Aragón, María. (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Domínguez, Marga (Institut Català d'Oncologia)
Rodríguez-Alonso, Lorena (Institut d'Investigació Biomèdica de Bellvitge)
Blasco, Alex (Hospital de Sant Joan Despí Moisès Broggi)
García-Rodríguez, Ana (Hospital de Viladecans)
Morros, Rosa (Universitat de Barcelona. Departament de Ciències Clíniques)
Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia

Date:	2019
Abstract:	There is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on colorectal cancer (CRC). We aimed to assess the association between CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) database that recorded patient diseases history and linked data on reimbursed medication. The study included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk associated to any statin exposure (OR = 0. 98; 95% CI: 0. 95-1. 01). Only in the stratified analysis by location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0. 87; 95% CI: 0. 81-0. 92). This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR723 Instituto de Salud Carlos III PI14-00613
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Scientific reports, Vol. 9 Núm. 1 (january 2019) , p. 13560, ISSN 2045-2322

DOI: 10.1038/s41598-019-49877-5
PMID: 31537841

8 p, 953.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles